Login to Your Account

Astex Strikes $500M Deal for its FGFR Inhibitor

By Nuala Moran

Wednesday, June 11, 2008
LONDON - Astex Therapeutics Ltd. sealed a deal worth a potential $500 million, licensing its fibroblast growth factor receptor (FGFR) inhibitor and agreeing on a drug discovery program around two cancer targets, with Janssen Pharmaceutica NV. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription